My Companies
Notification
Account
Log Out
Login
Biocon launched Yesafili, an interchangeable biosimilar to Eylea 2 mg, in the U.S., targeting a $5.89 billion reference product market. It is indicated for wet AMD and other eye conditions.
Biocon Secures Q1 2027 EU Launch For Pebrilzo After Genentech Settlement
Biocon Secures Japan Marketing Approval For Pegfilgrastim Biosimilar With Sandoz
Biocon Launches Yesafili Aflibercept Biosimilar Commercially In United States
Mylan Sells Entire 5.64% Biocon Stake In Open Market Deal